SCHEDULE: ARK & Wood Confirm 9.59% Stake in PacBio

ARK Investment Management LLC and Catherine D. Wood have filed an amendment confirming their joint beneficial ownership of 9.59% of Pacific Biosciences of California, Inc. common stock as of June 30, 2026.

Summary

• ARK Investment Management LLC and Catherine D. Wood have jointly filed Amendment No. 7 to Schedule 13G, confirming their beneficial ownership of Pacific Biosciences of California, Inc. (PacBio) common stock.
• As of June 30, 2026, the aggregate amount beneficially owned by both ARK and Catherine D. Wood is 29,781,416 shares, representing 9.59% of the class of securities.
• ARK Investment Management LLC holds sole voting power over 27,781,961 shares and shared voting power over 327,377 shares.
• Catherine D. Wood holds shared voting power over 28,109,338 shares.
• ARK Investment Management LLC has sole dispositive power over 29,781,416 shares.
• Catherine D. Wood has shared dispositive power over 29,781,416 shares.
• The filing confirms that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to the confirmation of significant beneficial ownership and the ongoing strategic investment by ARK and Catherine Wood, without immediate negative indicators.

Positives

• Confirmation of a substantial, stable ownership stake (9.59%) by significant institutional investors (ARK and Catherine Wood) in Pacific Biosciences of California, Inc.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a long-term investment perspective rather than a short-term activist play.
• The joint filing agreement under Rule 13d-1(k)(1) streamlines reporting and indicates a coordinated approach to their investment.

Negatives

• No new financial performance data or strategic updates are provided in this specific filing, as it is purely an ownership disclosure.
• The filing does not offer insights into the future investment strategy or conviction level beyond the current holdings.

Risks

• Potential for future changes in ownership percentage, which could impact market sentiment or strategic direction.
• The concentration of ownership by a single entity (ARK and Wood) could lead to significant market impact if they decide to divest or increase their stake substantially.

Future Outlook

This filing is an amendment to a Schedule 13G and does not contain forward-looking statements or specific guidance regarding the company's future performance. It solely pertains to ownership disclosure.

Management Comments

• ARK Investment Management LLC and Catherine D. Wood agree to file an Amendment No. 7 on Schedule 13G relating to their ownership of the Common Stock of the Issuer.
• They further agree that said Amendment No. 7 on Schedule 13G shall be filed on behalf of each of them.
• Certification: 'the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.'

Industry Context

StockSavvy.ai notes that this filing by ARK Investment Management and Catherine Wood, prominent investors in disruptive technologies, regarding Pacific Biosciences (a leader in long-read sequencing technology) highlights continued institutional interest in the genomics and biotechnology sector. This sector is characterized by rapid innovation and significant capital investment.

Stakeholder Impact

• Shareholders: The confirmation of a significant stake by ARK and Catherine Wood may be viewed positively, indicating confidence in the company's long-term prospects, potentially stabilizing or increasing investor interest.
• Management and Board: The substantial ownership by ARK and Wood could influence board composition or strategic decisions if their stake were to increase further or if they chose to engage more actively.
• Competitors: This filing reinforces the competitive landscape in the genomics sector, where significant institutional investors are actively participating.

Next Steps

• Continued monitoring of ARK Investment Management and Catherine D. Wood's ownership stake in Pacific Biosciences of California, Inc.
• Observation of any future amendments to Schedule 13G filings that may indicate changes in ownership or investment strategy.

Key Dates

Keywords

Pacific Biosciences, PacBio, ARK Investment Management, Catherine Wood, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management